A review on,

ARTIFICIAL INTELLIGENCE IN PHARMA SPACE

Alia Ajim Shaikh [1*], Akshay Ashok Thorat[2*], Chandani Uttam Kamble [3]

[1,2] *Nootan College of Pharmacy, Kavathemahankal, Dist- Sangli.*

[3]*Department of Pharmaceutical Quality Assurance.*

[3]*Nootan college of pharmacy, kavathemahankal.*

Abstract

A subfield of computer science called artificial intelligence (AI) gives robots the ability to analyze complicated data and operate more productively. AI-focused research has grown significantly, and its application to healthcare services and research is developing at a faster rate. The advantages and difficulties of AI in medical and pharmaceutical industry are covered in detail in this paper. This article discussed in great detail the use of AI in medication discovery and pandemic or epidemic predictions. The most popular artificial intelligence (AI) technologies are deep learning and neural networks; prospective technologies for clinical trial design are Bayesian nonparametric models; wearable technology and natural language processing are employed for patient identification and clinical trial monitoring. In order to predict the outbreaks of COVID-19, Zika, Ebola, and seasonal influenza, deep learning and neural networks were utilized. The scientific community may see quick and affordable advances in pharmaceutical and healthcare research as well as better public services thanks to the development of AI technologies. The pharmaceutical sector is leading the way in the deployment of artificial intelligence (AI), utilizing state-of-the-art technologies to transform research and medication development procedures. The industry's dedication to using AI for innovation and efficiency is demonstrated by strategic agreements and job possibilities, even in the face of a drop in patent filings. Beyond the pharmaceutical industry, artificial intelligence has an impact on many other businesses. This analysis highlights the several AI-based techniques used in pharmaceutical technology. However, the pharmaceutical industry's ongoing exploration and investment in AI present great opportunities for improving patient care and drug development procedures.

Keywords: *Artificial Intelligence, Pharmaceutical Industry, AI Tools, Drug Discovery, Machine learning, Deep Learning, Natural Language Programming, Graph Neural Networks*

Introduction:

Multitudinous assiduity are seeking to enhance their progress in order to meet the demands and prospects of their guests, using colourful methodologies. The pharmaceutical assiduity is a critical field that plays a vital part in saving lives. It operates rested on nonstop invention and the handover of new technologies to address global healthcare challenges and respond to medical extremities, similar as the recent epidemic. In the pharmaceutical assiduity, invention is generally rested on expansive exploration and development across colourful disciplines, including but not limited to manufacturing technology, packaging considerations, and client- acquainted marketing strategies. New pharmaceutical inventions range from small medicine motes to biologics, with a preference for better stability and high energy to fulfil unmet conditions in the treatment of conditions. The assessment of the significant situations of bane associated with new medicines is an area of considerable concern, challenging expansive exploration and disquisition in the foreseeable future. One of the primary points of the pharmaceutical assiduity is to give medicine motes that offer optimal benefits and are suitable for use in the healthcare assiduity. Despite this, the pharmaceutical assiduity faces multitudinous obstacles that bear farther advancement using technology- driven styles to address worldwide medical and healthcare demands.[1]

AI has been applied in colourful fields of society similar as game playing, computer vision, speech recognition, and expert system in health care and economics. In particular, the donation of AI in drug and health care has brought about changes in not only the health system but also cases. The foremost operation of AI in drug dates to 1964, with the pot of scientists from multidisciplinary exploration fields for the DENDRAL design. The success of this scientific sense is one reason for the explosive spread of AI in biomedicine in the 1970s. Another early operation of AI to health care was medical individual decision support systems, which appeared in 1954. Over the last 60 times, there has been a huge swell of AI technologies in health care. This change is reflected by not only the rapid-fire- fire- fire increase in the number of papers in AI in drug and health care, but also the appearance of AI in colorful medical fields.[2]

Artificial Intelligence and Machine Learning are powering inconceivable changes across a huge range of diligence. But in data and exploration- dependent diligence similar as medicinal, they 're having an unequaled jolt. From perfecting seeker election processes for clinical trials, to accelerating new medicine evolution, AI is snappily getting an essential device for those that want to stay competitive in this dynamic assiduity.[12]

To understand the impact of AI technology, let's talk about what kind of technologies are called "AI" in a nutshell and what they're used for. Substantially, technology specialists define three directions:



Fig: three directions of AI technology

Data wisdom algorithms are automated algorithms designed to dissect once conditioning and produce indispensable opinions. For illustration, it can give a more effective treatment plan or medicine combination grounded on the case's clinical data and medical history.

Machine literacy algorithms are a more complicated way of decision- making analysis grounded on neural network analytics. It works with given datasets to prognosticate decision consequences and classify and classify information. This is a quick and dependable way to produce marketing strategies or conduct clinical trials.

Deep literacy is grounded on more complicated forms of literacy and natural language processing, it's used for more detailed opinion. It can dissect sensitive images like skin conditions or radiology reviews and combine entered data with literal treatment issues or other case-specific information to produce the most suitable result.[3]

- **The role of AI in of pharmaceutical industry:**

1.AI for Drug Discovery:

Structure-Activity Relationship (SAR) Modeling: AI models can establish links between the chemical structure of composites and their natural Activity. This allows experimenters to optimize medicine campaigners by designing motes with desirable features, similar as high energy, selectivity, and favorable pharmacokinetic biographies.[1]

an end-to-end deep neural network used by the AlphaFold, trained to produce protein structures from amino acid sequences, multiple sequence alignments, and homologous proteins.[10]

2.AI in clinical trials:

While AI easily has important operations within clinical trials, maybe the most instigative and biggest change that it's bringing to the pharmaceutical assiduity is that in numerous cases, it's cutting the number of trials that need to be completed to reach a meaningful conclusion. By directly prognosticating how medicines will interact with trial cases, AI can effectively reduce the total number of clinical trials by over to 70. Basically, the analysis and sapience offered by AI helps remove some of the arbitrary rudiments that hamper clinical trials, reducing the need to compensate for those factors with a larger trial group.[12]

Supervised learning predicts clinical trial outcomes by training on historical data. It uses patient characteristics, treatments, and outcomes to predict patient response, efficacy, or safety. This helps optimize patient selection and trial design.[1]

3. AI in manufacturing:

Perhaps the first industry that springs to mind when discussing AI and process control is manufacturing. AI can assist with streamlining procedures that need numerous personnel, such as quality control and maintenance specialists.

Artificial intelligence (AI) tools can handle the most complex functionality, maximizing production. It guarantees that work will be completed with extreme precision. In addition to producing excellent work, it may assess the procedures, identify their weak points, enhance decision-making, and identify areas for process simplification.[3]

4.AI in pharmaceutical research and development:

The facilitation of exploration and development(R&D) is may be the most common use case for AI operations in the pharmaceutical assiduity. There are multitudinous results for rooting and organizing exploration data from clinical trial notes and other medical documents. Also, there is software that can purportedly dissect data from images of medicine composites at the molecular position.

It's possible that the pharmaceutical industry's most frequent use case for AI applications is to support research and development (R&D). Research data can be extracted and organized in a variety of ways from clinical trial notes and other medical documentation. Furthermore, there is software that allegedly has the ability to perform molecular analysis on data derived from pictures of pharmacological molecules.

The majority of software providers who provide solutions for drug research and development claim to be adept at big data analytics and microscopic imaging of molecular medicinal molecules. On the other hand, by gathering data from unstructured data sources to be used in the testing of present and potential therapeutic compounds, natural language processing software could improve drug development.

Applications for natural language processing could look through earlier research papers for discoveries that are now more pertinent to the research of a pharmaceutical business than they were at the time of discovery. This can comprise statistics and digitized lab notes stored in the R&D database of the pharmaceutical company.[4]

What is natural language programming: The area of artificial intelligence that deals with computers' comprehension and processing of human language is called natural language programming. It is an interdisciplinary field that brings together artificial intelligence, computer science, and linguistics.

NLP is utilized in many different applications, such as voice recognition, chatbots, and machine translation. Additionally, new approaches to teaching computers to understand human language are developed through NLP research.

Since natural language processing (NLP) is a complicated area, considerable research remains to be done to create more efficient techniques for teaching computers to comprehend and process language. NLP, however, has a wide range of possible uses, and the field has enormous potential for AI in the future.[6]

AI Tools used in pharmaceutical companies:

AI Tools	**Description/usage**	**Reference**
Autoencoders	In drug development, autoencoders are unsupervised learning models that are utilized for feature extraction and dimensionality reduction. They can help in compound screening and virtual screening as well as capture important features of molecules.	[1]
Bayesian network	These data are being successfully analyzed using graphical models for multivariate analysis such as Bayesian networks (BN) and others. They have enabled a previously unattainable high-resolution insight into the mechanisms underlying disease. Understanding the biological underpinnings of health and illness has made it easier to pinpoint the right targets for drug discovery and has sped up the process of getting improved medications into the hands of people who need them. The use of Bayesian networks and their significance to the drug discovery and development process are briefly explained in this chapter.	[14]
Graph Neural Networks (GNNs)	Graph Neural Networks (GNNs) are becoming more and more popular in the drug development field because of their capacity to handle a wide range of data types with ease, capture essential structural information, and depict complex molecular structures as networks. Distinct GNN models created for forecasting potent medication combinations, analyzing the drawbacks and advantages of each model, and contrasting the predicted efficacy of each model. We also go over the drug synergism prediction datasets and how drug-related data is extracted to create predictive characteristics.	[15]
Recurrent Neural Networks (RNNs)	The efficacy of advanced model-based control technologies, which are considered essential for enabling continuous pharmaceutical manufacture, depends on the caliber of the model derived from system identification. These technologies provide to enhance the control of CQAs. Several exacting physics-based models with distinct physical interpretations have been put forth to explain various API reactions.	[16]
Long Short-Term Memory Networks (LSTMs)	LTSM networks are used for drug design, protein homology detection, and protein subcellular localization prediction. A cell state can have information added or removed by an LSTM network. Gates serve as monitoring structures for this process. Gates allow information to flow through them. They are made up of a point-to-point multiplication operation and a sigmoid neural net layer.	[17]
Generative Adversarial Networks (GANs)	Pharmaceutical businesses can prioritize the manufacture and testing of virtual drugs with a higher chance of success by utilizing Generative AI. This targeted strategy lowers the requirement for costly and time-consuming experimental work, which eventually results in cost savings and lowers the risks related to medication development.	[18]
Deep Q-Networks (DQNs)	By forecasting a compound's activity and recommending high-potential candidates for additional testing, deep reinforcement learning and deep learning networks	[1]

	(DQNs) have been used to optimize drug discovery operations.	

Table: AI tools in pharmaceutical industry.

5. AI in Forecasting of an Epidemic/Pandemics:

Pandemics have no boundaries and can result in both morbidity and death. Numerous pandemic outbreaks have occurred worldwide, including the COVID-19 outbreak, the Spanish flu, the Black Death, cholera, influenzas, and AIDS. These outbreaks have the potential to disrupt societal and economic systems. Early diagnosis and effective treatment of the illness are critically dependent on each other, which lessens the toll that it has on people's health as well as on the political, social, and economic institutions. One of the main tools for achieving early detection is surveillance.[11]

- **Benefits of AI for Pharma companies:**

Every year, as we advance to a new degree of digitalization, pharmaceutical businesses confront increasingly complex issues. The pharmaceutical and life science sectors are searching for increasingly sophisticated and decision-making solutions as the amount of data about our everyday activities and health only increases.

The advent of AI technology forces us to embrace digitalization and put the most important pharmaceutical processes in their "hands." It will maximize the use of your resources and make many facets of your pharmaceutical company more inventive and successful.

The application of AI solutions had a big influence on performing medical research, developing improvements for patient care, and making decisions. Additionally, your business may carry out quality control and predictive maintenance on medication combinations thanks to artificial intelligence pharmaceutical automation.[3]

- **Challenges and opportunities of AI in pharma:**

The pharmaceutical sector has both opportunities and difficulties from artificial intelligence. In one-way, artificial intelligence (AI) boosts productivity and creativity by speeding up drug discovery, enhancing clinical trials, and streamlining supply chains.[19]

Challenges:

1.Smaller Datasets: In order for AI systems to learn, they often require large datasets. It is quite difficult to create large data for each sort of medical condition because there are many diseases and illnesses and comparatively few incidents of each.[20]

2.Regulation: The pharmaceutical sector is subject to stringent regulations that mandate complete transparency and disclosure at every stage of the drug development process. This requirement frequently results in longer and more expensive pharma AI development. To everyone's advantage, pharmaceutical companies and authorities should work together to expedite this process. In order to increase the value and efficacy of regulatory operations, businesses and regulators alike can embrace AI and other digital transformation projects.[20]

3.biases in data: Like any other technology generative models are unable to independently identify Biases by nature. "Despite its name, artificial intelligence is not intelligent in the human sense it cannot even comprehensive bias."

Most of what Gen AI loans come from the data it is trained on. "There is a high chance that the AI will reproduce these biases in its outputs if the data itself contains biases." [21]

4.Effect on employment:

The pharmaceutical business saw a 60% decrease in new job postings in Q4 2023 when compared to the prior quarter. The number of job posts fell by 79% on a yearly basis. Notably, with a 20% quarterly decline in new job postings, life, physical, and social science occupations ranked as the top AI-related job titles in the pharmaceutical industry in Q4 2023, with a share of 50%. With a share of 25% in Q4 2023, management occupations placed in second, with a 60% decrease in new job posts from the previous quarter. Healthcare professionals and technical occupations, with a

13% share of new job postings, and computer and mathematical occupations, with a 13% share in Q4 2023, are the other prominent AI roles.[9]

5.Interpretation of Results:

Even for professionals in the area, AI models can produce outputs that are challenging to understand due to their complexity. Clinicians and researchers may find it difficult to comprehend and interpret the results if the models are unable to clearly explain how they came to their conclusions. It could occasionally be challenging to interpret the data into useful information for medication development or clinical practice. Further limiting their use is the possibility that using AI models may demand a technical proficiency that not all researchers and practitioners possess. Therefore, enhanced interpretability and explainability of AI models are required to guarantee that their prediction can be understood and utilized effectively.[1]

6. Lack of Transparency:

AI models are sometimes referred to as "black boxes" since it is challenging to comprehend how the model makes its predictions. These models are made using intricate algorithms. Because of this lack of transparency, it may be difficult to convince regulators to approve AI-based drug development tools and difficult to prove the model is producing trustworthy and accurate predictions. Moreover, a lack of openness may also contribute to a lack of confidence in the model's predictions, especially if those forecasts differ from what researchers or doctors would expect. [1]

- **Futuristic overview:**

In the future, artificial intelligence (AI) could transform the pharmaceutical sector by speeding up medication research and discovery. Virtual screening methods will expedite lead compound identification by quickly analyzing massive chemical libraries and identifying therapeutic candidates with necessary properties. By examining genomes, proteomes, and medical data, AI-enabled precision medicine may be able to classify patients, forecast treatment outcomes, and personalize medications. Using generative models and deep learning, scientists can produce novel molecules with target-binding properties that increase drug efficacy and decrease side effects. AI will also enable dose formulations tailored to individual patients. AI algorithms will take into account patient-specific factors including age, weight, genetics, and sickness state to optimize medication formulations and delivery techniques and improve treatment outcomes. Because AI algorithms can forecast the toxicity and side effects of potential drugs, safety assessment will undergo a revolution.

- **Discussion and conclusion:**

With the help of artificial intelligence (AI) and big data, computational pharmaceutics transforms the drug distribution process by offering a more effective, economical, and data-driven method. It makes it possible to optimize medication formulations, customize treatments, comply with regulations, and minimize risk, all of which eventually result in better drug manufacturing procedures and better patient outcomes. All things considered, the incorporation of AI technology has enormous potential to expedite drug development, enhance patient outcomes, and completely transform the pharmaceutical sector, propelling it from an era 4.0 to an era 5.0.

In conclusion, despite swings in the number of patent applications and job advertising, artificial intelligence is transforming the pharmaceutical sector through creative patents and calculated investments. The application of AI is propelling global pharmaceutical innovation forward by improving research and drug development procedures.

References:

1. Sharma A, et al. Artificial intelligence in drug discovery. PMC 2019; 10385763: 1-9.

2. Torrado JC, et al. Artificial intelligence in pharmacogenomics. J Med Internet Res 2019; 21(11): e15511.

3. Viseven. Artificial intelligence in pharma industry. Viseven 2022; [dated]: 1-5.

4. Emerj. Artificial Intelligence for Pharmaceutical Research and Development. (Online) https://emerj.com/ai-sector-overviews/artificial-intelligence-pharma-research-development/

5. TechTarget. Natural language processing (NLP). TechTarget 2022; [dated]: 1-2.

6. Autoblocks. Natural language programming. Autoblocks 2022; [dated]: 1-2.

7. Gupta A, et al. Question answering systems: A systematic literature review. Res Gate 2022; 350550855: 1-12.

8. Xenonstack. Generative AI in pharmaceutical. Xenonstack 2022; [dated]: 1-6.

9. Pharmaceutical Technology. Artificial intelligence in pharma. Pharm Technol 2022; [dated]: 1-4.

10. Inside Precision Medicine. The art of AI in drug discovery. Inside Precis Med 2022; [dated]: 1-5.

11. MDPI. Support vector machines (SVMs) in pharmaceutical research. MDPI 2022; 7(1): 10-18.

12. The Smart Cube. How AI is shaping the future of pharmaceutical industry. Smart Cube 2022; [dated]: 1-6.

13. Research Gate. Artificial intelligence and machine learning in pharmaceutical industry. Res Gate 2022; 374914821: 1-10.

14. Research Gate. Application of Bayesian network in drug discovery and development process. Res Gate 2022; 283597890: 1-8.

15. Springer. Artificial intelligence in drug development. Springer 2022; 10(1): 10669-10676.

16. MDPI. Artificial intelligence in pharmaceutical research. MDPI 2022; 6(11): 242-252.

17. Science Direct. Long short-term memory networks in pharma research. Sci Direct 2022; [dated]: 1-6.

18. Sakpal P. Generative AI in pharmaceutical market. LinkedIn Pulse 2023; [February 18]: 1-5.

19. Scilife. AI in pharma: innovation and challenges. Scilife Blog 2022; [dated]: 1-6.

20. Spiceworks. Top challenges faced by pharma AI. Spiceworks 2022; [dated]: 1-5.

21. Pharmaceutical Technology. Can pharma overcome generative AI's bias problem? Pharm Technol 2022; [dated]: 1-4.